Loading...
 

Vaginal suppository of 6300 IU vitamin D stopped vaginal infection – Feb 2011

Chronical cervical infections and dysplasia (CIN I, CIN II)-vaginal vitamin D (high dose) treatment: a new effective method.

Arch Gynecol Obstet. 2011 Feb 12.
Schulte-Uebbing C, Schlett S, Craiut ID, Antal L, Olah H.
Umweltmedizinisches Therapiezentrum am Dom, München, Endokrinology, Oncology, Immunology, Toxicology, CT Ultrasound, Private Laboratory, Weinstr. 7 A, 80333, Munich (near Marienplatz), Germany, prof-schulte-uebbing at t-online.de.

INTRODUCTION: We evaluated data of 200 patients with chronical recurrent cervical infections despite adequate treatment (=primary antibiotic/antimycotic treatment according to the antibiogram and secondary vaginal lactobacillus treatment): 100 of them with chronical bacterial and/or fungal infections had no dysplasia. 100 of them with chronical bacterial and/or fungal infections had dysplasia (50 with a CIN I and 50 with a CIN 2). 43 of the 50 CIN I patients (=86%) and 46 of the 50 CIN II patients (= 92%) had high risk HPV.

METHODS: The patients got a high-dose vaginal vitamin D treatment (12,500 IU, 3 nights a week, for 6 weeks).

RESULTS: Vitamin D serum levels: we could find that obviously vitamin D is reabsorbed by the vaginal mucosa. Before treatment, 100 patients (=50%) had insufficient vitamin D serum values (<30 ng/ml). After treatment, 58 of these 100 patients (=58%) had adequate vitamin D serum values (30-50 ng/ml). In our anamnesis after 6 weeks of treatment, most of the patients subjectively declared to have less vaginal infections, less discharge and sexual intercourse problems.
This we could also find objectively 6 weeks after the treatment.
Cervicitis and no dysplasia group: after 6 weeks of treatment, only 7% still had a bacterial and/or fungal cervicitis (=success rate 93%).
The treatment also seems to have longer time effects. After 6 months of treatment, more than 80% had no bacterial and/or fungal cervicitis.

Cervicitis and CIN I group: After 6 weeks of treatment, only 10% still had a bacterial and/or fungal cervicitis. Success rate was 90%. 21 of 43 patients (=49%) still had high risk of HPV, and the success rate was 51%. 24 patients (=48%) were free of dysplastic cells (PAP II or PAP I, only 2 of the 24 patients still had high risk HPV). 26 patients (=52%) still had a CIN I [19 of them (36%) had high risk HPV], and the success rate was 48%.

Cervicitis and CIN II group: after 6 weeks of treatment, 8 of the 50 patients (16%) still had a bacterial and/or fungal cervicitis, and the success rate was 84%. 38 of 46 patients (=83%) still had high risk HPV, and the success rate was 17%. 9 patients (=18%) were free of dysplastic cells (PAP II or PAP I, 7 of the 9 patients were free of high risk HPV) and 44% had a better result (CIN I, 5 of the 22 patients were free of high risk HPV). 24 patients still had a CIN II (all of them still had high risk HPV), and the success rate was 62% (very successful 18%, successful 44%).

CONCLUSION: When compared with the ineffective lactobacillus vaginal suppositories, the high-dose vitamin D vaginal suppositories were effective.
Most of the 200 patients subjectively and objectively had benefit.
The high-dose vitamin D vaginal treatment might be an option for the therapy and prophylaxis of chronical cervical infections and of a dysplasia of the cervix uteri (CIN 1, CIN 2).

PMID: 21318370


See also VitaminDWiki



See any problem with this page? Report it to the webmaster.

Health Problems and D

  # of studies as of 12/20/14